GlassScriptPhysician profile
Nare Torosyan
NPI 1245729466
$1,715.10
in general payments reported to CMS, 2019-2025
12 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $274 · 2023: $325 · 2024: $603 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,440.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $535.11 | 2023-2025 | Lifevest |
| Edwards Lifesciences Corporation | $220.27 | 2024 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $210.55 | 2024-2025 | Watchman Flx, General - Therapies, Latitude Communicator Power Supply |
| Janssen Pharmaceuticals, INC | $144.71 | 2022 | |
| Shockwave Medical, INC | $143.91 | 2025 | |
| Abiomed | $141.20 | 2025 | |
| Biotronik INC. | $129.73 | 2022 | |
| Biosense Webster, INC. | $50.00 | 2024 | Carto 3 |
| Pfizer INC. | $46.26 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $39.93 | 2023 | Evkeeza, Praluent |
| Teleflex LLC | $34.46 | 2023 | Guideliner |
| Actelion Pharmaceuticals US, INC. | $18.97 | 2023 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nare Torosyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.